HIV

Program’s ability to address adverse effects found to improve outcomes.

The FDA has lifted the indefinite deferral of blood donation for men who have sex with men.

Researchers achieve promising first step in new HIV treatment approach.

Alpha therapy shows promise in selectively killing infected cells from the central nervous system.

Most read HIV articles from the past year.

Several barriers prevent many health care providers from prescribing pre-exposure prophylaxis to patients at high risk for HIV.

Taking drug around periods of sexual activity lowers transmission rates.

An HIV pre-exposure prophylaxis program piloted at a pharmacy in Seattle shows promising results for patients.

Pharmacists can help patients with HIV through refill reminders, pillboxes, or delivering medications to homes or workplaces.

Taking antiretroviral therapy exactly as prescribed is not only essential for lowering the amount of HIV in an infected individual, but also critical for reducing the risk of transmission.

Researchers find link between HIV infection and stroke.

Novel small ubiquitin-like modifier protease inhibitor drug class shows promise.

In June of 1981 an unspeakable new disease entered the public consciousness in the United States and it did so quickly and unexpectedly, leaving illness, tragedy, and death in its wake.

New treatments for HIV infection are desperately needed.

New research may allow for HIV to be attacked at its core.

Statins show promise to reduce liver disease incidence in coinfected patients.

On-demand PrEP before and after sexual activity could reduce the incidence of HIV-1 in men who have sex with men.

Researchers weigh risk and reward in starting early antiretroviral therapy in patients with HIV.

Research may lead to gel that prevents transmission of HIV, hepatitis C and the Ebola virus.

Clean needle programs have reduced HIV incidence among injection drug abusers by 80% from 1990 to 2006.

Higher number of unprotected sexual encounters correlates with enhanced cell expressions.

Likelihood of co-infection linked closely to intravenous drug use more often than risky sexual activities in patients with HIV and hepatitis C.

Micronutrient deficiencies in patients with HIV causes high prevalence of anemia and inflammation.

The $750 per pill price of pyrimethamine could soon be undercut by a new compound selling for $1 per pill.

How pharmacists can have a positive impact on the treatment of patients with HIV.